PA
CGON icon

Parallel Advisors’s CG Oncology CGON Stock Holding History

Parallel Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11
Closed -$744 – 3946
2026
Q1 		$744 Buy
+11
New +$623 ﹤0.01% 3593
2025
Q1 		– Sell
-3
Closed -$86 – 3534
2024
Q4 		$86 Sell
3
-14
-82% -$479 ﹤0.01% 3452
2024
Q3 		$641 Buy
+17
New +$596 ﹤0.01% 3137

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallel Advisors's CGON Position: Q2 2026 in Review

Parallel Advisors sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 11 shares — an estimated $744 sold.

Parallel Advisors first reported a position in CGON in Q3 2024 and held it in 3 quarters. The position peaked at $744 in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Parallel Advisors reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
  • Parallel Advisors sold 11 CG Oncology shares in Q2 2026, an estimated $744.
  • Parallel Advisors first reported a position in CG Oncology in Q3 2024 and held it in 3 quarters.
  • Parallel Advisors's CG Oncology position peaked at $744 in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.